Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation Common Stock (DXR) represents a pioneering medical instrumentation and biotechnology company focused on the accurate measurement of blood volume. Daxor develops and markets the BVA-100 (Blood Volume Analyzer), which stands as the first FDA-cleared diagnostic tool capable of providing precise, objective quantification of blood volume status and composition compared to patient-specific norms. This technology is pivotal across a wide range of medical conditions.
The BVA-100 has revolutionized blood volume measurement, a practice that has historically been prone to lengthy and inaccurate testing processes. Traditional methods often took 4 to 8 hours and yielded inconsistent results. In contrast, the BVA-100 can deliver accurate and reliable measurements quickly, enhancing the capabilities of physicians who previously had to rely on less precise tests that measured blood thickness, often leading to misleading outcomes in critical medical situations.
Daxor Corporation, headquartered in New York, is at the forefront of medical technology and innovation. The company's recent achievements include the development of the next generation of Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes. These advancements are not only enhancing the quality of patient care but also strengthening the company's market position.
Financially, Daxor has shown robust growth, with unaudited revenue climbing 229.1% in the first two months of 2024 year-on-year. The company's strong start to 2024 is indicative of its commitment to innovation and excellence. Daxor is also actively engaged in strategic partnerships and investor relations, with Bret Shapiro serving as the Senior Managing Partner at CORE IR, ensuring transparent and effective communication with investors and stakeholders.
In addition to its technological developments, Daxor is also a notable presence in the medical community, participating in significant events such as the Premier Event for Cardiovascular Industry Leaders and Clinicians. The company's research and publications, such as those presented at the American College of Cardiology Scientific Sessions and in the American Heart Journal, underscore its dedication to advancing medical knowledge and practice.
Daxor (DXR) announced new research findings from Duke University Medical Center and Yale School of Medicine presented at the Technology and Heart Failure Therapeutics Conference (THT) in February 2025. The studies focus on the company's Blood Volume Analysis (BVA) technology.
The Duke study revealed no correlation between pulmonary artery pressure readings and actual blood volume measured by BVA, challenging industry assumptions about pressure monitoring as a proxy for volume measurement in heart failure care.
The Yale study, conducted over 5 years, examined diuretic mechanism of action using BVA, demonstrating the technology's accuracy in detecting volume shifts. The research provided new insights into the fluid removal process and highlighted BVA's potential to improve treatment for millions of patients on diuretic therapy.
TruLite Health, developer of health equity solutions, has expanded its leadership team with key appointments. Walter D. Conwell, MD, MBA, former chief diversity officer at Morehouse School of Medicine, has been appointed as president. The company also added two board members: Edmondo Robinson, MD, MBA, a digital health leader and Ardent Health Services board member, and Caleb DesRosiers, JD, MPA, a pharmaceutical executive.
TruLite's main product, Truity™, is software that integrates with electronic health records to address clinical bias at the point of care. The solution uses explainable AI and machine learning to drive patient-specific clinical, social, and behavioral interventions, aiming to improve healthcare outcomes and costs. The software aligns with regulatory requirements from the Joint Commission, CMS, and FDA.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, will exhibit at the Society for Critical Care Medicine (SCCM) 2025 Critical Care Congress in Orlando, FL from February 23-25, 2025, at Booth #532.
The company's Blood Volume Analysis (BVA) technology has demonstrated significant impact in ICU settings, where there are 5.7 million annual admissions costing $108 billion in the United States. Peer-reviewed studies show BVA technology alters fluid and red blood cell interventions in 44% of cases and reduces mortality by 66% in surgical intensive care units, while also decreasing hospital stays and ventilator days.
Daxor (Nasdaq: DXR) announces a breakthrough study published in JACC: Case Reports revealing a distinct heart failure phenotype through their blood volume analysis (BVA) technology. The research, examining 179 advanced heart failure patients, identified that 20% (36 patients) exhibited a specific hypervolemia/polycythemia phenotype characterized by expanded blood volume overload and elevated red blood cells.
The condition potentially affects 700,000-1,400,000 US heart failure patients, representing 10-20% of ambulatory cases. Four patients received therapeutic phlebotomy treatment guided by BVA, resulting in significant symptom improvement with zero hospitalizations or deaths over a 12-month monitoring period. The study highlights that patients with this phenotype typically show worse clinical outcomes and face higher stroke and blood clot risks if untreated.
Daxor (Nasdaq: DXR) announces a multicenter study published in the Journal of Cardiac Failure demonstrating the superiority of their Blood Volume Analysis (BVA) technology in heart failure treatment. The study, involving 255 heart failure patients across Mayo Clinic, Duke University Medical Center, and Baptist Hospital in Memphis, revealed that BVA outperforms standard hemodynamic measurements in assessing heart failure volume status.
The research, titled 'Patient Sex Impacts Volume Phenotypes and Hemodynamics in Chronic Heart Failure,' highlighted three key findings: hemodynamic pressure measures are less accurate compared to BVA, the technology enables more precise anemia diagnosis, and sex-specific volume differences require individualized treatment approaches. The study confirms BVA's 98% accuracy in volume measurement, establishing it as a important tool for precise heart failure diagnosis and treatment.
Daxor (DXR) announces expansion of its ezBVA Lab blood volume analysis service to two new health systems. The expansion includes an Arizona-based multi-campus medical center for outpatient nephrology care and a regional health network serving Southwest Iowa, Nebraska, Minnesota, and North Dakota for heart failure outpatient management.
The ezBVA Lab service provides cost-effective blood volume analysis with minimal initial investment and broad reimbursement coverage. The company reports this expansion contributes to their strongest quarter ever in terms of revenue and year-over-year growth.
Daxor (NASDAQ: DXR), the global leader in blood volume measurement technology, will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall'24 Conference from October 17-19, 2024, in Aurora, CO. This elite conference unites cardiovascular thought-leaders to transform care and introduce innovative solutions.
Daxor's CEO, Michael Feldschuh, emphasized the opportunity to showcase their BVA-100™ Blood Volume Diagnostic, which addresses key challenges in cardiovascular care. Peer-reviewed studies have shown that BVA-guided care significantly improves patient outcomes, including:
- 82% reduction in 30-day mortality
- 86% reduction in 1-year mortality
- 56% reduction in 30-day readmissions
- 57% reduction in length of stay when performed upon admission
The BVA technology provides 98% accurate, actionable data for optimizing treatment plans and individualizing care, ultimately improving outcomes while reducing duration and cost.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, announces its participation in the 2024 Maxim Healthcare Virtual Summit. CEO and President Michael Feldschuh will engage in a fireside chat with Maxim's Director of Research and Senior Healthcare Analyst Anthony Vendetti on Tuesday, October 15, 2024, at 10:00 AM ET.
The summit runs from October 15 – 17, 2024. Investors can access the fireside chat via webcast at https://m-vest.com/events/healthcare-10152024. Mr. Feldschuh will also be available for one-on-one meetings with registered summit investors. Interested parties can contact Bret Shapiro at CORE IR by calling 1-516-222-2560 or emailing brets@coreir.com to arrange meetings.
Daxor (NASDAQ: DXR), a leader in blood volume measurement technology, announces its participation in the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024. The event, scheduled for September 27-30 in Atlanta, will feature Daxor's Blood Volume Analysis (BVA) technology. Key highlights include:
1. Exclusive BVA showcase in the 'Devices in Heart Failure' session
2. Product presentation in the main Exhibit Hall
3. Corporate Member Meeting with HFSA leadership
Daxor's CEO emphasizes the importance of BVA in personalizing treatment and improving patient outcomes. BVA-guided treatment has shown significant reductions in heart failure readmissions, mortality rates, and hospital stays. Daxor will be exhibiting at Booth 225 during the conference.
Daxor (Nasdaq: DXR) announces a pivotal review published in Cardiorenal Medicine highlighting the important role of Blood Volume Analysis (BVA) in managing cardiorenal syndrome (CRS). The review, authored by expert contributors, emphasizes BVA's significance in enhancing the precision of diuretic and red cell therapies, leading to improved patient care and outcomes. Key findings include:
- BVA's 98% accuracy in measuring total blood and red blood cell volumes
- BVA's potential to optimize personalized therapy for CRS patients
- Projected growth of CRS patient population to 47 million by 2030
Daxor's CEO, Michael Feldschuh, emphasizes BVA technology's potential to improve outcomes while reducing care duration and costs in CRS management.
FAQ
What is the current stock price of DAXOR (DXR)?
What is the market cap of DAXOR (DXR)?
What does Daxor Corporation specialize in?
What is the BVA-100?
How has the BVA-100 improved blood volume measurement?
What are some recent achievements of Daxor Corporation?
How has Daxor performed financially in early 2024?
Who is the Investor Relations Contact at Daxor Corporation?
What kind of medical events does Daxor participate in?
Where has Daxor Corporation published its research findings?
What is the significance of the BVA-100 in medical practice?
Where is Daxor Corporation headquartered?
